Molnupiravir (Lageviro®)

Infectious diseases
NHS Lothian

Consider a 5-day course of molnupiravir for adults with COVID-19 who:

  • do not need supplemental oxygen for COVID-19 and
  • are within 5 days of symptom onset and
  • are thought to be at high risk of progression to severe COVID-19 (See list included in this document and NICE TA878) and
  • where nirmatrelvir/ritonavir (Paxlovid®) is contraindicated or unsuitable.

When assessing the person, take into account their likely response to any vaccinations already given, any comorbidities or risk factors, and whether their condition is deteriorating.

Do not offer molnupiravir to children and young people aged under 18, or pregnant women.

Dosing

The recommended dose of molnupiravir is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days.

For contraindications, cautions and interactions please consult the SmPC and BNF.